Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eliem Therapeutics, Inc. (ELYM)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Mar-05-23 | Dec-31-22 | Dec-05-22 | Sep-30-22 | Sep-05-22 | Jun-30-22 |
| | 10-Q | 10-Q | 8-K | 10-K | 8-K | 10-Q | 8-K | 10-Q |
| Revenues [+] | 7.1 | 31.1 | 5.7 | 0.0 | 4.9 | 0.0 | 4.3 | 0.0 |
| Royalties | | | 5.7 | | 4.9 | | 4.3 | |
| Revenue growth | | 135.4% | -30.8% | | -28.4% | | -28.9% | |
| Cost of goods sold | 0.0 | 0.0 | 11.4 | 0.0 | 9.6 | 0.0 | 8.7 | 0.0 |
| Gross profit | 7.1 | 31.1 | -5.7 | 0.0 | -4.6 | 0.0 | -4.5 | 0.0 |
| Gross margin | 100.0% | 100.0% | -100.0% | | -93.9% | | -105.4% | |
| Selling, general and administrative [+] | 3.0 | 17.7 | 17.7 | 9.6 | 4.6 | 4.5 | 4.5 | 4.9 |
| General and administrative | 3.0 | 17.7 | 17.7 | 16.5 | 4.6 | 4.5 | 4.5 | 4.9 |
| Other selling, general and administrative | | | | -7.0 | | | | |
| Research and development | 3.7 | 5.7 | | | | 4.3 | | 8.8 |
| Other operating expenses | 6.7 | 24.3 | | -45.1 | 0.3 | | -0.2 | |
| EBIT [+] | -6.3 | -16.7 | -23.4 | 35.6 | -9.6 | -8.7 | -8.7 | -13.7 |
| EBIT growth | -53.9% | 26.9% | 78.5% | 42.5% | -10.7% | -6.8% | -6.8% | 57.4% |
| EBIT margin | -88.8% | -53.5% | -409.8% | | -193.9% | | -205.4% | |
| Non-recurring items | 0.4 | 6.8 | | | | | | |
| Interest income | 1.1 | | | | 0.8 | | | 0.1 |
| Interest income | 1.1 | | | | 0.8 | | | 0.1 |
| Other income (expense), net [+] | 0.4 | 1.1 | 23.4 | -43.3 | 1.0 | -0.9 | -0.9 | -1.0 |
| Gain (loss) on foreign currency transactions | -0.4 | 0.2 | | | -1.0 | | 1.3 | 1.0 |
| Other non-operating income | | | | | | 0.4 | | |
| Other | 1.5 | 1.1 | | 1.9 | | -0.9 | 0.4 | -0.9 |
| Pre-tax income | -5.2 | -22.3 | 0.0 | -7.8 | -7.8 | -9.7 | -9.7 | -14.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -5.2 | -22.3 | 0.0 | -7.8 | 0.0 | -9.7 | 0.0 | -14.6 |
| Net margin | -73.4% | -71.6% | 0.0% | | -0.2% | | -0.2% | |
| |
| Basic EPS [+] | ($0.19) | ($0.84) | | ($0.30) | ($0.29) | ($0.37) | ($0.37) | ($0.56) |
| Growth | -65.0% | 67.2% | | -39.7% | -26.8% | -47.6% | -47.6% | -82.2% |
| Diluted EPS [+] | ($0.19) | ($0.84) | | ($0.30) | ($0.29) | ($0.37) | ($0.37) | ($0.56) |
| Growth | -65.0% | 67.2% | | -39.7% | -26.8% | -47.6% | -47.6% | -82.2% |
| |
| Shares outstanding (basic) [+] | 26.8 | 26.5 | | 26.3 | 0.0 | 26.3 | 0.0 | 26.3 |
| Growth | 2.1% | 1.0% | | 114.6% | 0.6% | 69.0% | 69.0% | 653.9% |
| Shares outstanding (diluted) [+] | 26.8 | 26.5 | | 26.3 | 0.0 | 26.3 | 0.0 | 26.3 |
| Growth | 2.1% | 1.0% | | 114.6% | 0.6% | 69.0% | 69.0% | 653.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|